540788 ASPIRA

Aspira Pathlab & Diagnostics Share Price

 

 

Start SIP in ASPIRA

Start SIP

Performance

  • Low
  • ₹62
  • High
  • ₹65
  • 52 Week Low
  • ₹50
  • 52 Week High
  • ₹107
  • Open Price₹65
  • Previous Close₹64
  • Volume1,864

Investment Returns

  • Over 1 Month -12.94%
  • Over 3 Month -7.63%
  • Over 6 Month + 13.17%
  • Over 1 Year + 1.87%

Smart Investing Starts Here Start SIP with Aspira Pathlab & Diagnostics for Steady Growth!

Invest Now

Aspira Pathlab & Diagnostics Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 19.1
  • PEG Ratio
  • 0
  • Market Cap Cr
  • 65
  • P/B Ratio
  • 4.5
  • Average True Range
  • 4.03
  • EPS
  • -
  • Dividend Yield
  • 0
  • MACD Signal
  • -0.14
  • RSI
  • 46.34
  • MFI
  • 20.87

Aspira Pathlab & Diagnostics Financials

Aspira Pathlab & Diagnostics Technicals

EMA & SMA

Current Price
₹63.06
-1.38 (-2.14%)
pointer
  • Bearish Moving Average 14
  • Bullish Moving Average 2
  • 20 Day
  • ₹65.07
  • 50 Day
  • ₹64.84
  • 100 Day
  • ₹64.14
  • 200 Day
  • ₹62.68

Resistance and Support

63.51 Pivot Speed
  • R3 67.37
  • R2 66.07
  • R1 64.81
  • S1 62.25
  • S2 60.95
  • S3 59.69

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Aspira Pathlab & Diag has an operating revenue of Rs. 24.52 Cr. on a trailing 12-month basis. An annual revenue growth of 64% is outstanding, Pre-tax margin of 9% is okay, ROE of 27% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading close to its key moving averages, around -0% and 0% from 50DMA and 200DMA. It needs to stay above these levels to make any further meaningful move. It has recently broken out of a base in its weekly chart but failed to keep its momentum and is trading around -9% from the pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 72 which is a FAIR score but needs to improve its earnings, a RS Rating of 62 which is FAIR indicating the recent price performance, Buyer Demand at D- which indicates heavy supply, Group Rank of 34 indicates it belongs to a strong industry group of Medical-Services and a Master Score of B is close to being the best. Overall, the stock definitely has some strength, you may want to examine it in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Aspira Pathlab & Diagnostics Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-12 Quarterly Results
2025-08-12 Quarterly Results
2025-05-16 Audited Results
2025-02-07 Quarterly Results
2024-11-12 Quarterly Results

Aspira Pathlab & Diagnostics F&O

Aspira Pathlab & Diagnostics Shareholding Pattern

18.39%
60.16%
21.45%

About Aspira Pathlab & Diagnostics

  • NSE Symbol
  • ASPIRA
  • BSE Symbol
  • 540788
  • Managing Director & CEO
  • Dr. Pankaj J Shah
  • ISIN
  • INE500C01017

Similar Stocks to Aspira Pathlab & Diagnostics

Aspira Pathlab & Diagnostics FAQs

Aspira Pathlab & Diagnostics share price is ₹63 As on 03 January, 2026 | 18:18

The Market Cap of Aspira Pathlab & Diagnostics is ₹64.9 Cr As on 03 January, 2026 | 18:18

The P/E ratio of Aspira Pathlab & Diagnostics is 19.1 As on 03 January, 2026 | 18:18

The PB ratio of Aspira Pathlab & Diagnostics is 4.5 As on 03 January, 2026 | 18:18

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23